Abstract
The aim of this study was to investigate the pharmacokinetics and pharmacodynamics of puerarin loaded carboxymethyl chitosan microspheres (Pue‐CCMs). The differences in pharmacokinetics parameters of rats after intragastric administration of Pue‐CCMs and puerarin were investigated using HPLC. To assess the protective effect of Pue‐CCMs on myocardial injury in rats, serum levels of creatine kinase (CK), lactate dehydrogenase (LDH), total superoxide dismutase (T‐SOD), and malondialdehyde (MDA) were measured, in addition to pathological examinations and immunohistochemical staining. Our present study has shown that the AUC0–t, Cmax, Tmax, MRT0–t of Pue‐CCMs, and puerarin were 20.176 mg·h/L, 3.778 μg/mL, 1 h, 4.634 h and 9.474 mg·h/L, 2.618 μg/mL, 0.542 h, and 3.241 h, respectively. Pue‐CCMs alleviated myocardial ischemic injury. Pretreatment with Pue‐CCMs could significantly decrease CK, LDH, and MDA levels and increase T‐SOD level in the serum. Pue‐CCMs downregulated expression of the Bcl‐2 associated X protein (Bax) and upregulated B‐cell lymphoma‐2 (Bcl‐2) expression. Compared with puerarin group, the Pue‐CCMs group could improve the oral bioavailability of puerarin. The protective effect of Pue‐CCMs against myocardial injury was significantly greater than puerarin at the same dose. In summary, Pue‐CCMs should be a qualified and promising candidate as a new oral preparation of puerarin.
Funding Information
  • National Natural Science Foundation of China (81373944, 2012KTCQ03-13)

This publication has 20 references indexed in Scilit: